Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Kee** ILCs in shape: PD-1 as a metabolic checkpoint
Anti-PD-1 immunotherapy has emerged as a revolutionary therapeutic strategy against cancer. However, it often leads to undesired side effects. In this issue, a new study reports how PD-1 signalling drives meta...